alexa Challenges In Development Of Biologics And Biosimilars: An Overview
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

Joint Event: 3rd International Conference on Biopharmaceutics and Biologic Drugs & 5th International Pharmacy Conference
August 31-September 01, 2017 Philadelphia, USA

Mallikarjun Narayan Dixit
Accutest Biologics Private Limited, India
Keynote: J Bioequiv Availab
DOI: 10.4172/0975-0851-C1-029
The global prescription drug market is expected to grow by 6% to reach nearly USD 1.05 trillion by 2022. The top 20 drugs are manufactured by 14 companies and account for a total 10% of global prescription drug market in 2016. The total revenue generated by top 20 products was estimated to be USD 0.128 trillion. Biologic drugs are cost effective opportunity for patients in the area of oncology, diabetes, inflammatory disorders, Autoimmune diseases, cardiovascular diseases and represent a total market value of more than $50 billion. There are 150 marketed biologic products worldwide, with almost 500 products under development. About 21 important biologics will loose patent protection by the year 2019. The biopharmaceuticals show much greater efficacy and efficiency when compared to conventional pharmaceuticals. The use of biopharmaceuticals is continuously increasing and has resulted in a huge market demand. Biological drug products including Biosimilars, are larger in size and more complex than conventional small molecule drugs and the majority of these originate from living organisms. During the product development phase, some of the process changes are inevitable such as Cell line change, Critical Raw Material change, Primary packaging components change, Scale up/ down, Process parameter change, Formulation, Presentation, Device and Form Change Site Change or Critical Equipment change. Multiple complex manufacturing processes involved in biologics drug product development may significantly affect the product quality attributes, product development process and the product safety and/or efficacy. These may also affect the other quality attributes such as physical, chemical, biological, or microbiological property of the biologic drug product. There are multiple challenges at every stage of development of high quality biologics drug products. These include the initial clone development, clone expression, product development, processing, purification, characterization, post translation modifications, sensitive bioanalytical methods and stringent regulatory expectations. Similarly, there are several challenges in the clinical development phase also. These include Study Indication, Study Design, reference product, regulatory approvals, patient recruitment, Inclusion and Exclusion Criteria, Statistical consideration, Immunogenicity, Safety assessment and Post marketing study requirement. The advancement in the technology and availability of scientific approaches have helped to a great extent in effectively combating the challenges andkeep the biologics drug development process at a rapid pace. The presentation on challenges in developing Biologics and Biosimilars gives an overview of scope for Biologics and Biosimilars drugs, various challenges and methods to overcome many of these challenges.

Dixit (graduate from University of Illinois) is a scholastic personality with several patents and publications to his credit and with more than 25 years of rich experience in pharmaceuticals, biopharmaceutical and CRO industries in the area of drug discovery and bio-analytical services. He has extensively worked on method development and validation of various assay platforms such as LC-MS, ELISA, MSD, SPR, RIA/RIPA and Cell based assays for Immunogenicity and pharmacokinetics evaluation of non-clinical and clinical study samples under GLP and GCLP compliant practices for regulatory submission studies. As a test facility management and head of bioanalytical laboratory he has successfully faced multiple sponsor’s and regulatory audits. Dr. Dixit with his expertise is currently guiding the team biologics in the delivery of quality compliant bioanalytical and Characterization services for biologics and biosimilars for submission studies.

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

1-702-714-7001Extn: 9037

Business & Management Journals


1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version